68Gallium PSMA-11 PET/CT Scan for the Detection of Sites of Biochemical Recurrent or Metastatic Prostate Cancer

Inclusion Criteria

• Patients must meet at least one of the following three criteria: * Patients with suspected BCR of prostate cancer following initial treatment with either prostatectomy or definitive EBRT of the prostate. BCR is defined as at least two consecutive increases in PSA of > 0.2 ng/mL in patients treated with prostatectomy and for patients originally treated with EBRT the prostate specific antigen (PSA) is > 2 ng/mL above nadir post radiation therapy * Patients with known metastatic prostate who have failed systemic therapy * Patients are being considered as candidates for salvage therapy
• Patients must be older than 18 years of age
• Patients must be medically stable as judged by the patient’s physician
• Patients must be able to lie still for a total of 20 – 40 minutes for the PET/CT scans
• Ability to understand and the willingness to sign a written informed consent
• Patients with BCR and no known lesions should not be on antiandrogen therapy at the time of scans. Patients with known metastases who are currently being treated with anti-androgen therapy may remain on this medication

Exclusion Criteria

• Patients who have or have had a biopsy proven concurrent other malignancy, excluding skin cancers
• Patients may not weigh more than the maximum weight limit for the PET/CT scanner table (> 200 kg or 440 pounds [lbs])
• Patient must not be claustrophobic